Resources from the same session
2274 - ACHIEVE-2 trial: a randomized phase III trial investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with high-risk stage II colon cancer (CC)
Presenter: Takayuki Yoshino
Session: Adjuvant treatment duration for high-risk stage II colon cancer
Resources:
Abstract
Slides
Webcast
How do you treat high-risk stage II colon cancer patients? Nothing vs. FP vs. doublet including MSI high patients
Presenter: Claus-Henning Koehne
Session: Adjuvant treatment duration for high-risk stage II colon cancer
Resources:
Slides
Webcast
IDEA collaboration for HR stage II
Presenter: Alberto Sobrero
Session: Adjuvant treatment duration for high-risk stage II colon cancer
Resources:
Slides
Webcast
SCOT trial
Presenter: Timothy Iveson
Session: Adjuvant treatment duration for high-risk stage II colon cancer
Resources:
Slides
Webcast
TOSCA trial
Presenter: Sara Lonardi
Session: Adjuvant treatment duration for high-risk stage II colon cancer
Resources:
Slides
Webcast
HORG trial
Presenter: Ioannis Souglakos
Session: Adjuvant treatment duration for high-risk stage II colon cancer
Resources:
Slides
Webcast
Panel discussion
Presenter: Claus-Henning Koehne
Session: Adjuvant treatment duration for high-risk stage II colon cancer
Resources:
Slides
Webcast
New IDEA collaboration ‘CIRCULATE IDEA’
Presenter: Takayuki Yoshino
Session: Adjuvant treatment duration for high-risk stage II colon cancer
Resources:
Slides
Webcast